Overview

Clinical Study of Compound Ciwujia Granules in the Treatment of Depression

Status:
NOT_YET_RECRUITING
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the therapeutic efficacy and safety of Compound Ciwujia Granules in treating depression disorder (heart-spleen deficiency syndrome). The study primarily aims to address the following key questions: * Can Compound Ciwujia Granules effectively alleviate depressive symptoms in patients with heart-spleen deficiency syndrome? * What adverse reactions might participants experience while taking Compound Ciwujia Granules? Researchers will compare Compound Ciwujia Granules to a placebo (a look-alike substance that contains no drug) to see if Compound Ciwujia Granules works to treat depression disorder. Participants are required to complete the following procedures: 1. Take Compound Ciwujia Granules or placebo twice daily for 8 weeks; 2. Continue concomitant SSRIs throughout the treatment period; 3. Return to the hospital for scheduled assessments at Week 4 and Week 8; 4. Complete a 4-week follow-up period after the 8-week treatment phase.
Phase:
PHASE4
Details
Lead Sponsor:
Shanghai Mental Health Center
Collaborator:
Heilongjiang Quanle Pharmaceutical Co., Ltd.